Unaudited Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 18,841,000	$ 10,383,000	$ 45,311,000	$ 28,077,000
General and administrative	6,643,000	4,674,000	17,930,000	15,353,000
Total operating expenses	25,484,000	15,057,000	63,241,000	43,430,000
Loss from operations	(25,484,000)	(15,057,000)	(63,241,000)	(43,430,000)
Interest income	33,000	495,000	437,000	1,782,000
Other income (expense)	1,000	0	(6,000)	151,000
Loss before income tax benefit	(25,450,000)	(14,562,000)	(62,810,000)	(41,497,000)
Income tax benefit	0	(125,000)	(3,695,000)	(116,000)
Net loss	(25,450,000)	(14,437,000)	(59,115,000)	(41,381,000)
Comprehensive loss	$ (25,449,000)	$ (14,437,000)	$ (59,114,000)	$ (41,381,000)
Net loss per common share:
Basic and diluted (in dollars per share)	$ (0.27)	$ (0.35)	$ (0.87)	$ (1.00)
Weighted average common shares outstanding:
Basic and diluted (in shares)	92,675	41,552	67,931	41,486